Active, Not Recruiting
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
NCT03279692
- Conditions
- Central Nervous System Neoplasms, High Grade Meningioma, Meningeal Neoplasms, +8 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Massachusetts General Hospital Boston, Massachusetts, United States